Clinical Trials
13 trialsNCT03192397 2026-04-14
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting
NCT03842696 2026-01-27
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting
NCT06299462 2025-02-25
PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
Phase 1/2 Recruiting
NCT00423514 2022-12-27
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01744223 2022-07-12
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Active not recruiting
NCT02145403 2022-01-03
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT00555048 2017-05-24
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT02337595 2016-04-22
45RA_NEG_DLI
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Completed
NCT00506922 2015-04-28
Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00002790 2015-03-06
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
Fred Hutchinson Cancer Center
Phase 1/2 Withdrawn
NCT00089037 2011-07-15
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00248430 2010-09-21
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00010283 2010-04-02
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
Fred Hutchinson Cancer Center
Phase 1/2 Completed